Shares of Aimed Bio, a corporations developing antibody-drug conjugate (ADC) new drugs, hit the upper limit (the top of the daily price band) on the second day of listing on the 5th.

The KOSDAQ Market Division of the Korea Exchange (KRX) holds a listing ceremony for Aimed Bio at the Seoul headquarters' PR hall on the morning of the 4th. Pictured after the ceremony are Kim Dae-young, vice chair of the Korea IR Association; Min Kyung-wook, head of the KOSDAQ Market Division at the Korea Exchange (KRX); Heo Nam-gu, CEO of Aimed Bio; Nam Do-hyun, chair (CTO) of Aimed Bio; Seong Joo-wan, executive vice president of Mirae Asset Securities; and Kang Wang-rak, vice chair of the KOSDAQ Association. /Courtesy of Korea Exchange (KRX)

As of 9:15 a.m. that day, Aimed Bio shares were trading on the KOSDAQ market at 57,200 won, up 30.00% (13,200 won) from the previous session.

Earlier, on the first day of its KOSDAQ listing on the 4th, Aimed Bio succeeded in a "double-double" (a fourfold rise from the offering price) and closed at 44,000 won, up 300% from the offering price (11,000 won).

Aimed Bio is a corporations founded in 2018 by neurosurgeon Nam Do-hyeon of Samsung Medical Center and develops antibody-drug conjugate (ADC) new drugs. An antibody-drug conjugate is a therapeutic technology that attaches a drug to an antibody to deliver it precisely to target cells.

※ This article has been translated by AI. Share your feedback here.